DGX Quote, Financials, Valuation and Earnings

Delcath Systems has a net margin of 8.3% compared to Quest Diagnostics's net margin of 5.4%. Quest Diagnostics's return on equity of 13.14% beat Delcath Systems's return on equity of -40.28%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 7.41%. On the other hand Delcath Systems has an analysts' consensus of $24.08 which suggests that it could grow by 49.46%. Given that Delcath Systems has higher upside potential than Quest Diagnostics, analysts believe Delcath Systems is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.524, which suggesting that the stock is 47.572% less volatile than S&P 500. In comparison Delcath Systems has a beta of 0.722, suggesting its less volatile than the S&P 500 by 27.805%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.78%. Delcath Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Delcath Systems pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are larger than Delcath Systems quarterly revenues of $19.8M. Quest Diagnostics's net income of $220M is higher than Delcath Systems's net income of $1.1M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.65x while Delcath Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.91x versus 9.89x for Delcath Systems. Usually stocks with elevated PS ratios are considered overvalued.

Danaher has a net margin of 8.3% compared to Quest Diagnostics's net margin of 16.62%. Quest Diagnostics's return on equity of 13.14% beat Danaher's return on equity of 7.38%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 7.41%. On the other hand Danaher has an analysts' consensus of $247.05 which suggests that it could grow by 33.87%. Given that Danaher has higher upside potential than Quest Diagnostics, analysts believe Danaher is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.524, which suggesting that the stock is 47.572% less volatile than S&P 500. In comparison Danaher has a beta of 0.804, suggesting its less volatile than the S&P 500 by 19.561%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.78%. Danaher offers a yield of 0.61% to investors and pays a quarterly dividend of $0.32 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Danaher pays out 19.7% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are smaller than Danaher quarterly revenues of $5.7B. Quest Diagnostics's net income of $220M is lower than Danaher's net income of $954M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.65x while Danaher's PE ratio is 35.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.91x versus 5.66x for Danaher. Usually stocks with elevated PS ratios are considered overvalued.

Labcorp Holdings has a net margin of 8.3% compared to Quest Diagnostics's net margin of 6.36%. Quest Diagnostics's return on equity of 13.14% beat Labcorp Holdings's return on equity of 9.01%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 7.41%. On the other hand Labcorp Holdings has an analysts' consensus of $273.90 which suggests that it could grow by 12.93%. Given that Labcorp Holdings has higher upside potential than Quest Diagnostics, analysts believe Labcorp Holdings is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.524, which suggesting that the stock is 47.572% less volatile than S&P 500. In comparison Labcorp Holdings has a beta of 0.826, suggesting its less volatile than the S&P 500 by 17.43%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.78%. Labcorp Holdings offers a yield of 1.19% to investors and pays a quarterly dividend of $0.72 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Labcorp Holdings pays out 32.59% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are smaller than Labcorp Holdings quarterly revenues of $3.3B. Quest Diagnostics's net income of $220M is higher than Labcorp Holdings's net income of $212.8M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.65x while Labcorp Holdings's PE ratio is 28.04x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.91x versus 1.55x for Labcorp Holdings. Usually stocks with elevated PS ratios are considered overvalued.

Waters has a net margin of 8.3% compared to Quest Diagnostics's net margin of 18.34%. Quest Diagnostics's return on equity of 13.14% beat Waters's return on equity of 40.75%.

Quest Diagnostics has a consensus price target of $183.92, signalling upside risk potential of 7.41%. On the other hand Waters has an analysts' consensus of $388.19 which suggests that it could grow by 12.07%. Given that Waters has higher upside potential than Quest Diagnostics, analysts believe Waters is more attractive than Quest Diagnostics.

Quest Diagnostics has a beta of 0.524, which suggesting that the stock is 47.572% less volatile than S&P 500. In comparison Waters has a beta of 1.138, suggesting its more volatile than the S&P 500 by 13.849%.

Quest Diagnostics has a quarterly dividend of $0.80 per share corresponding to a yield of 1.78%. Waters offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Quest Diagnostics pays 38% of its earnings as a dividend. Waters pays out -- of its earnings as a dividend. Quest Diagnostics's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Quest Diagnostics quarterly revenues are $2.7B, which are larger than Waters quarterly revenues of $661.7M. Quest Diagnostics's net income of $220M is higher than Waters's net income of $121.4M. Notably, Quest Diagnostics's price-to-earnings ratio is 21.65x while Waters's PE ratio is 31.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Quest Diagnostics is 1.91x versus 6.92x for Waters. Usually stocks with elevated PS ratios are considered overvalued.